New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical Care
22 févr. 2019 08h37 HE
|
Daxor Corporation
NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
Daxor Corporation Appoints Guido Manzo, Vice President of Sales
23 janv. 2019 08h30 HE
|
Daxor Corporation
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the...
Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin
10 janv. 2019 08h30 HE
|
Daxor Corporation
NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation of Hypertension
13 nov. 2018 08h30 HE
|
Daxor Corporation
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients
30 oct. 2018 08h30 HE
|
Daxor Corporation
Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality NEW YORK , Oct. 30, 2018 (GLOBE...
Daxor Corporation to Present at The MicroCap Conference on October 2, 2018
25 sept. 2018 08h30 HE
|
Daxor Corporation
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, today announced...
New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements
17 sept. 2018 08h30 HE
|
Daxor Corporation
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
Daxor Corporation Appoints Kathryn A. Kornafel Vice President of Marketing and Commercial Development
12 juin 2018 08h30 HE
|
Daxor Corporation
NEW YORK , June 12, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces...
A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use
19 avr. 2018 09h00 HE
|
Daxor Corporation
New York, NY, April 19, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the publication of new...
Daxor to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House
05 avr. 2018 09h00 HE
|
Daxor Corporation
New York, NY, April 05, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces it will present at...